SecBot SecBot
SC 13G ·Filed Nov 16, 2026

YARW

Yarrow Bioscience, Inc.
NEUTRAL
Impact 3/10
Horizonimmediate Processed1d 5h ago SEC0001193125-26-462440
Passive investor 5%+ stake
Actionable Insight • Neutral

Monitor for any future 13D conversion or increased activism from any of the recent institutional filers, though all current filings certify passive intent.

DirectionNeutral
Confidencehigh
Horizonimmediate
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Ameriprise Financial disclosed an 8.6% passive beneficial ownership stake in Yarrow Bioscience as of September 30, 2026, primarily through its Columbia Small Cap Growth Fund (6.3%). This adds to a series of recent 13G filings by other institutions following Yarrow's September 2026 equity offering, with no activist intent indicated.

Key Financial Metrics

Stake
8.6%
Stake Value
$15.7M
Investor
Ameriprise Financial, Inc.
Investor Type
mutual fund

Key Facts

  • Ameriprise Financial, Inc. disclosed a 8.6% beneficial ownership stake in Yarrow Bioscience as of September 30, 2026.
  • The stake comprises 739,538 shares of common stock, with 539,115 shares held by Columbia Small Cap Growth Fund (6.3%).
  • The filing is a passive Schedule 13G under Rule 13d-1(b), certifying no intent to influence control.
  • This follows recent 13G filings by Bellevue Group (10.6%), Spruce Street Capital (6.4%), and others after Yarrow's $172.5M September 2026 equity offering.

Financial Impact

8.6% passive stake valued at approximately $15.7M based on $183M market cap

ownership concentration

Risk Factors

  • No activist intent is indicated, but a cluster of institutional filings could precede coordinated engagement.
  • Yarrow is a pre-revenue clinical-stage biotech with high cash burn and no approved products.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 2 SEC documents filed with EDGAR.

DocumentAccession Number
SC 13G Filing (Primary)0001193125-26-462440
Document: 0001193125-26-462440.txt0001193125-26-462440

Track record

13 reports on YARW

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 17, 2026today SC 13G/A Neutral 3/10 Entry $13.93 Now $14.27 +2.44% settles Dec 16
  2. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $14.20 Now $14.27 +0.49% settles Dec 16
  3. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $13.93 Now $14.27 +2.44% settles Dec 16
  4. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $13.93 Now $14.27 +2.44% settles Dec 16
  5. Nov 16, 20261d ago SC 13G/A Neutral 3/10 Entry $15.44 Now $14.27 −7.58% settles Dec 15
  6. Nov 16, 20261d ago SC 13G Neutral 3/10 Viewing Entry $18.20 Now $14.27 −21.59% settles Dec 15
  7. Nov 16, 20261d ago SC 13G/A Neutral 3/10 Entry $18.03 Now $14.27 −20.85% settles Dec 15
  8. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $17.35 Now $14.27 −17.75% settles Dec 15
  9. Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $18.03 Now $14.27 −20.85% settles Dec 15
  10. Nov 12, 20265d ago 8-K Neutral 4/10 Entry $19.63 Now $14.27 −27.31% settles Dec 11
Showing 10 of 13

US Market Status

Market Open · Closes in 22m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 16, 2026